Qing Zhu, 51Oak Ridge, TN

2006008, Apr 20, 2006

Oct 14, 2005

11/249369

Lee Harold - Arlington VA, US
Qing Zhu - Herndon VA, US
Herbert Liebl - Wien, AT

MicroStrategy, Incorporated - McLean VA

G06F 17/00

715517000, 715522000, 715523000

A network-based system for enabling users connected over the network to an OLAP system to select formatting options for reports requested for processing by the OLAP system. The system enables a user to select the format for each report in a workbook or for a stand-alone report. The format specified may be multiple levels of format that are applied in a hierarchical manner including global formats that apply to all reports in a workbook, report formats which apply to specific reports in the workbooks, attribute/element/metric formats which apply to specific attributes, elements, and metrics of a report, and value formats which apply to specific values within an element of a report. The formats specified may also comprise merged report formats, combined grid and graphs within a report and an autoformat that enables each recipient of the report to specify the format in which that recipient views the report when the report is received.

2010029, Nov 25, 2010

Sep 24, 2008

12/679881

Jay A. Berzofsky - Bethesda MD, US
Qing Zhu - Bethesda MD, US

Office of Technology Transfer - Rockville MD

A61K 39/39
A61K 38/02
A61K 31/713
A61P 37/08
A61P 37/04
A61P 31/12
A61P 31/10
A61P 31/04
A61P 33/00

4241931, 4241841, 4242781, 4242041, 4242341, 4242651, 4242741, 514 11, 4242751, 514 37, 514 44 R

The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.

2012015, Jun 21, 2012

Dec 23, 2009

13/147051

Josephine McAuliffe - Gaithersburg MD, US
Frances Palmer-Hill - Gaithersburg MD, US
Qing Zhu - Gaithersburg MD, US
Joann Suzich - Gaithersburg MD, US

MEDIMMUNE, LLC. - Gaithersburg MD

A61K 39/12
C07K 14/00
A61P 37/04
C07K 14/765
A61K 38/16
A61P 31/12
G01N 33/566
C07K 16/00

4241861, 436501, 530325, 530324, 530350, 530363, 5303873, 514 214, 435 792

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

2023011, Apr 13, 2023

Nov 11, 2022

18/054757

- Gaithersburg MD, US
Qing ZHU - Gaithersburg MD, US
Godfrey Jonah RAINEY - Gaithersburg MD, US
Cuihua GAO - Gaithersburg MD, US
Srinath KASTURIRANGAN - Gaithersburg MD, US
Changshou GAO - Gaithersburg MD, US

C07K 16/10
A61P 31/16

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

2021007, Mar 18, 2021

Dec 1, 2020

17/108608

- GAITHERSBURG MD, US
Qing ZHU - Gaithersburg MD, US
Godfrey Jonah RAINEY - Gaithersburg MD, US
Cuihua GAO - Gaithersburg MD, US
Srinath KASTURIRANGAN - Gaithersburg MD, US
Changshou GAO - Gaithersburg MD, US

C07K 16/10
A61P 31/16

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

2020010, Apr 9, 2020

Sep 4, 2019

16/560040

- Gaithersburg MD, US
Qing ZHU - Gaithersburg MD, US
Godfrey Jonah RAINEY - Gaithersburg MD, US
Cuihua GAO - Gaithersburg MD, US
Srinath KASTURIRANGAN - Gaithersburg MD, US
Changshou GAO - Gaithersburg MD, US

C07K 16/10
A61P 31/16

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

2020010, Apr 9, 2020

Oct 8, 2019

16/596039

- Gaithersburg MD, US
- Bellinzona, CH
Josephine Mary McAuliffe - Gaithersburg MD, US
Frances Palmer-Hill - Gaithersburg MD, US
Leslie Wachter - Gaithersburg MD, US
Andy Yuan - Gaithersburg MD, US
Qing Zhu - Gaithersburg MD, US
Davide Corti - Bellinzona, CH
Antonio Lanzavecchia - Bellinzona, CH
Barbara Guarino - Bellinzona, CH
Anna DeMarco - Bellinzona, CH

C07K 16/10
A61K 31/13
A61K 39/395
A61K 31/7012
A61K 31/215
A61K 39/42
A61K 45/06
C12P 21/00
G01N 33/569
G01N 33/577

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

2018015, Jun 7, 2018

May 31, 2016

15/577799

- Gaithersburg MD, US
Qing ZHU - Gaithersburg MD, US
Godfrey Jonah RAINEY - Gaithersburg MD, US
Cuihua GAO - Gaithersburg MD, US
Srinath KASTURIRANGAN - Gaithersburg MD, US
Changshou GAO - Gaithersburg US, US

C07K 16/10
A61P 31/16

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.